AtriCure Inc
$ 27.10
-0.62%
05 Jun - close price
- Market Cap 1,372,370,000 USD
- Current Price $ 27.10
- High / Low $ 28.15 / 26.78
- Stock P/E N/A
- Book Value 9.71
- EPS -0.10
- Next Earning Report 2026-07-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.01 %
- 52 Week High 43.18
- 52 Week Low 25.36
About
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
Analyst Target Price
$47.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-17 | 2025-10-29 | 2025-07-29 | 2025-04-29 | 2025-02-12 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-07-25 |
| Reported EPS | 0.0022 | 0.06 | -0.01 | -0.02 | -0.14 | -0.08 | -0.17 | -0.17 | -0.25 | -0.21 | -0.2 | -0.12 |
| Estimated EPS | -0.06 | -0.04 | -0.11 | -0.16 | -0.22 | -0.1488 | -0.2 | -0.17 | -0.23 | -0.23 | -0.31 | -0.31 |
| Surprise | 0.0622 | 0.1 | 0.1 | 0.14 | 0.08 | 0.0688 | 0.03 | 0 | -0.02 | 0.02 | 0.11 | 0.19 |
| Surprise Percentage | 103.6667% | 250% | 90.9091% | 87.5% | 36.3636% | 46.2366% | 15% | 0% | -8.6957% | 8.6957% | 35.4839% | 61.2903% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-28 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATRC
2026-06-04 17:45:00
AtriCure, Inc. (ATRC) has announced that its BoxX-NoAF clinical trial for atrial fibrillation treatment is advancing 12 months ahead of schedule, with patient enrollment expected to conclude by the end of 2026 and trial results potentially available in 2027. This development follows strong Q1 2026 earnings, which saw a 14.3% year-over-year revenue jump, exceeding analyst expectations, primarily driven by its pain management segment. Needham reiterated a Buy rating and a $45 price target, highlighting the accelerated trial timeline as a significant catalyst for unlocking new market opportunities.
2026-06-03 19:39:43
AtriCure, Inc. (Pharmaceuticals & Biotechnology sector) has recently hit a new 52-week low of USD 25.37, down from its 52-week high of USD 43.18, amidst significant stock volatility. Despite a one-year performance of 18.35%, it significantly lags behind the S&P 500's 28.2% performance. The company, with a market capitalization of USD 1,516 million, is currently loss-making with a negative return on equity and does not offer dividends, highlighting financial challenges.
2026-06-03 10:09:15
AtriCure Inc. stock has reached a new 52-week low of $25.39, trading just above its 52-week low of $25.52. Despite a 22% decline over the past year and 33% year-to-date, InvestingPro analysis suggests future profitability with analysts predicting profitability this year and revenue growth to $552 million, indicating the stock is currently undervalued. Needham recently reiterated a Buy rating and a $45.00 price target following strong Q1 2026 financial results, which showed revenue exceeding expectations and increased profitability.
2026-06-02 21:38:54
AtriCure Inc. (ATRC) stock has fallen to a new 52-week low of $25.39, representing a 22% decline over the past year and 33% year-to-date. Despite the downturn, analysts predict the medical device company will achieve profitability this year with revenue growing to $552 million, and InvestingPro indicates the stock is undervalued with price targets significantly above current levels. The company recently reported strong Q1 2026 financial results with notable revenue growth, leading Needham to reiterate its "Buy" rating.
2026-06-02 14:40:41
AtriCure Inc. (ATRC) stock hit a new 52-week low of $25.39, marking a significant decline of 22% over the past year and 33% year-to-date. Despite recent challenges, analysts predict profitability for the medical device company this year, with expected revenue growth of 15% to $552 million. InvestingPro suggests the stock is currently undervalued, with price targets ranging from $36 to $55, indicating substantial upside potential.
2026-06-02 13:40:41
This article highlights AtriCure, Inc. (NASDAQ: ATRC) as a top small-cap stock with significant growth potential. The medical device company recently exceeded Q1 2026 earnings estimates, reporting a 14.3% year-over-year revenue increase driven by its pain management segment. A key development is the accelerated timeline for the BoxX-NoAF clinical trial, with patient enrollment expected to conclude by the end of this year, potentially opening a major new market opportunity by 2027.
